Synopsis: CSRC Think Tank: Real World Data to Assess Cardiovascular Safety- Can We Improve Efficiencies in Phase 3 Development Posted on December 12, 2016December 12, 2016 by kadie.maness@duke.edu View the paper HERE
Practical Considerations for Assessing Cardiac Repolarization of Diabetes Drugs. Leader: Ingrid Hensley Posted on November 25, 2014July 25, 2016 by Cardiac Safety
How Can the TQT Study Be Replaced? The Role of Concentration Effect Modeling in QT Assessment. Leader: Borje Darpo Posted on November 25, 2014July 25, 2016 by Cardiac Safety
Designs and statistical approaches to assess CV risk of new type 2 diabetes therapies in development. Leader: Mary Jane Geiger Posted on November 25, 2014July 25, 2016 by Cardiac Safety
Hess C, et al. TransRadial Education And Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention. A report from the Cardiac Safety Research Consortium. Am Heart J. 2013; 165(3) : 344-353 Posted on November 25, 2013July 25, 2016 by Cardiac Safety View Paper Here
Christian J, et al. Cardiac Imaging for the Evaluation of Drug Induced Cardiotoxicity. Am Heart J. 2012; 164(6) : 846-855 Posted on August 13, 2012July 25, 2016 by Cardiac Safety View Paper Here
Kligfield P, et al. Cardiac Safety Research Consoritum ECG Warehouse: Database specifications and principles of use for algorithm development and testing. Am Heart J. 2010; 160(6):1023-1028 Posted on August 13, 2010July 7, 2016 by Cardiac Safety View Paper Here
Al-Khatib SM, et al. Planning the safety of atrial fibrillation ablation registry initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A cardiac safety research consortium “incubator” think tank. Am Heart J. 2010; 159(1): 17-24 Posted on August 13, 2010July 7, 2016 by Cardiac Safety View Paper Here
